GORES GUGGENH.A DL-,0001 Aktie

Vaxcyte has advanced its modified phase-2/3 study of the 31-valent pneumococcal conjugate vaccine VAX-31 in infants into the final phase and added an optimized dose arm; about 900 participants are expected to be enrolled. The company expects initial immunogenicity and safety data by the end of H1 2027, received expanded FDA Breakthrough Therapy support, and—despite earlier share declines—analysts still see significant upside potential. Firms such as Guggenheim and Cantor Fitzgerald maintain positive views, while Pro Research highlights Vaxcyte’s financial position. » More on de.investing.com

Guggenheim analyst Joseph Osha upgraded First Solar, Inc.'s price target to $287 from $202 and reiterated a Buy rating, citing stronger fundamentals driven by policy developments and industry trends. The firm’s position as a leader in thin‑film CdTe solar technology and a strong balance sheet underpin Guggenheim’s confidence. The note frames First Solar as well placed to benefit from favorable solar policy momentum. » More on finance.yahoo.com

Sionna Therapeutics has begun dosing in a randomized, double‑blind phase‑1 study to test dual combinations of the NBD1 stabilizer SION‑451 with other agents. Topline results are expected in mid‑2026; earlier phase‑1 data showed good tolerability, and analysts including Guggenheim and Stifel have reiterated buy ratings with price targets of $32 to $45. The company emphasizes the importance of the NBD1 domain for CFTR stabilization and plans a phase‑2b study based on the trial results. » More on de.investing.com